A clinical and pathological update on hepatocellular carcinoma

Area of Science:

• Oncology
• Pathology
• Molecular Biology

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern, with projections indicating over 1 million new cases annually by 2025.
• HCC exhibits distinct molecular subgroups, each correlating with specific morphological and phenotypic characteristics.
• Understanding these molecular differences is crucial for advancing HCC diagnosis and treatment.

Purpose of the Study:

• To highlight the importance of molecular subtyping in Hepatocellular Carcinoma (HCC).
• To emphasize the role of tissue biomarkers in clinical pathology for HCC patient management.
• To explore how improved diagnostic strategies can influence clinical decision-making regarding pre-treatment biopsies.

Main Methods:

• Analysis of molecular and genetic backgrounds of HCC subgroups.
• Evaluation of morphological and phenotypic features associated with HCC subtypes.
• Review of the potential impact of biomarker integration into routine pathology practice.

Main Results:

• Identification of two major molecular subgroups within HCC.
• Correlation between specific molecular subgroups and distinct morphological/phenotypic profiles.
• Demonstration of the utility of tissue biomarkers for patient stratification.

Conclusions:

• Molecular subtyping of HCC provides critical insights into disease heterogeneity.
• The integration of tissue biomarkers into pathology practice can enhance treatment allocation for HCC patients.
• Improved diagnostic accuracy through biomarker utilization may increase the frequency of pre-treatment biopsies, aiding in personalized medicine approaches for HCC.